JANX

Janux Therapeutics, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1817713Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$10.0M

Net Income FY2025

$(114.0M)

EPS (Basic, as reported)

$-1.83

Net Margin FY2025

-1136.3%

ROE FY2025

-11.9%

Total Equity

$957.0M

Shares Out

61M

Business description

Janux Therapeutics, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 0 → 10

Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025

Revenue04981110

Research & development(3)(26)(53)(55)(68)(126)

General & administrative(2)(10)(22)(26)(41)(42)

Operating income(5)(33)(67)(73)(99)(158)

Other income (expense), net(2)04153044

Income tax expense———000

Net income(7)(33)(63)(58)(69)(114)

EPS — basic——($1.52)($1.32)($1.28)($1.83)

EPS — diluted——($1.52)($1.32)($1.28)($1.83)

Shares outstanding — basic (M)0041445462

Shares outstanding — diluted (M)—2441445462

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.